Generic Acomplia Rimonabant 20mg Acomplia is a medicine that is used for treating obese or overweight people or people with extra weight.It may be used as an aid to smoking cessation and to improve high-density lipoprotein triglyceride levels and cholesterol .

Acomplia belongs to a family of drugs that are used in the treatment of obesity and related conditions.

• Acomplia acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism.
• Acomplia switches off brain circuits that make people hungry .
• CB1 receptor blockade with Acomplia acts to decrease the overactivity of the endocannabinoid system (EC system). The EC system is a recently characterised physiological system that includes receptors that have been shown to play an important role in regulating body weight and in controlling energy balance, as well as lipid (or fat) metabolism.

• Acomplia is used complementary to treat patients who suffer from Type 2 diabetes and abnormal levels of fat in the blood.
• Sanofi argues that Acomplia can also prevent the risk of cardiovascular disease.
• Patients with large waist circumference (102 cm in men and 88 cm in women) will mostly benefit from taking the drug.

• Acomplia has been studied by sanofi-aventis as an aid to smoking cessation based on studies for up to one year in over 6,500 smokers motivated to quit smoking.
• Sanofi-aventis submitted a New Drug Application to the FDA, which in turn issued a non approvable letter for Acomplia for use in smoking cessation. An approvable letter was however issued for Acomplia for use in weight management.

• No. Sanofi is still awaiting U.S. marketing go-ahead which it has said could come by the end of this year.
• Acomplia received European Union marketing approval in June 2006.
• U.S. health authorities have asked Sanofi for more information on Acomplia.
• The first launch will take place in Britain in July and be followed by launches in Denmark, Ireland, Germany, Finland and Norway in the second half of this year, according to Sanofi.

• In clinical studies, Acomplia has been shown to improve a wide array of cardiometabolic risk factors as well as promoting sustained weight loss4,5.
• Approximately half of the observed improvement in HDL-cholesterol, triglycerides and HbA1C (an indicator of blood sugar control) in patients who received Acomplia 20mg was beyond that expected from weight loss alone.

What is the shelf life of the pills?

• The expiry date is mentioned on each blister. It is different for different batches. The shelf life is 2 years from the date of manufacture and would differ from batch to batch depending on when they were manufactured.